$310.3 M

CRBP Mkt cap, 16-Oct-2019
Corbus Pharmaceuticals Net income (Q2, 2019)2.2 M
Corbus Pharmaceuticals EBIT (Q2, 2019)1.7 M
Corbus Pharmaceuticals Cash, 30-Jun-201973.2 M
Corbus Pharmaceuticals EV237.4 M

Corbus Pharmaceuticals Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

R&D expense

5.9m15.4m26.0m48.6m

General and administrative expense

3.6m6.5m9.0m13.0m

Operating expense total

9.5m21.9m35.0m61.6m

EBIT

(8.9m)(20.0m)(32.6m)(56.7m)

Interest expense

2.4k

Interest income

3.4k477.0183.1k982.8k

Net Income

(8.9m)(20.0m)(32.4m)(55.7m)

Corbus Pharmaceuticals Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

12.3m15.0m62.5m41.7m

Current Assets

12.7m17.4m65.5m44.2m

PP&E

124.1k435.3k1.4m2.7m

Total Assets

12.9m17.9m67.0m47.0m

Accounts Payable

1.3m3.4m3.1m6.3m

Short-term debt

162.0k271.8k332.9k394.3k

Current Liabilities

3.6m8.9m8.2m18.1m

Long-term debt

162.0k271.8k332.9k394.3k

Total Debt

324.0k543.5k665.7k788.6k

Total Liabilities

3.9m9.0m9.2m19.5m

Additional Paid-in Capital

22.3m42.2m123.5m148.9m

Retained Earnings

(13.3m)(33.3m)(65.7m)(121.4m)

Total Equity

9.0m8.9m57.8m27.5m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.4 x2 x1.2 x1.7 x

Corbus Pharmaceuticals Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(8.9m)(20.0m)(32.4m)(55.7m)

Depreciation and Amortization

43.9k87.7k255.7k493.9k

Accounts Payable

972.2k1.9m(885.8k)3.9m

Cash From Operating Activities

(4.6m)(13.6m)(27.8m)(30.1m)

Purchases of PP&E

(114.0k)(353.0k)(707.4k)(2.3m)

Cash From Investing Activities

(114.0k)(353.0k)(707.4k)(2.3m)

Long-term Borrowings

(190.1k)(239.0k)(354.2k)(430.2k)

Cash From Financing Activities

10.8m16.7m76.0m11.4m

Interest Paid

5.6k12.4k10.4k

Corbus Pharmaceuticals Ratios

USDY, 2019

EV/EBIT

139.2 x

EV/CFO

-39.1 x

Financial Leverage

1.8 x